Sanjeev Handa

Sanjeev Handa

Auto-generated profile, based on publicly available information

Sanjeev Handa

Department of Dermatology, Venereology and Leprology Postgraduate Institute of Medical Education and Research Chandigarh India

Research Focus & Metrics

Academic Career Length

31Years (1996-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 May 2003 in Pediatric Dermatology
Verified
Journal Article
Closed access
PDF file
SHSanjeev Handa
Sanjeev Handa
SDSunil Dogra
Sunil Dogra

1 February 2005 in Journal of the American Academy of Dermatology
Verified
Journal Article
Closed access
BKBikash Ranjan Kar
Bikash Ranjan Kar
SHSanjeev Handa
Sanjeev Handa
SDSunil Dogra
Sunil Dogra
BKBhushan Kumar
Bhushan Kumar

16 July 2002 in International Journal of Dermatology
Verified
Journal Article
Closed access
PDF file
SHSanjeev Handa
Sanjeev Handa
BSBijaylaxmi Sahoo
Bijaylaxmi Sahoo

1 January 2004 in Journal of Dermatological Treatment
Verified
Journal Article
Closed access
SHS Handa
S Handa
SDS Dogra
S Dogra
BKB Kumar
B Kumar
Objectives: Antihistamines are the first line of therapy for chronic idiopathic urticaria (CIU). The present study was designed considering the lack of reports comparing the efficacy and safety of commonly prescribed cetirizine and fexofenadine in the treatment of CIU. methods: A total of 116 patients, aged 17 to 65 years, with CIU (urticarial wheals for at least two days per week for six consecutive weeks before entry) were enrolled in this randomised double‐blind study. Study period was 28 days with patient visits on days 14 and 28 for investigator evaluation of the clinical response. Patient evaluation was on the basis of an analogue scale. Final response to treatment was judged as symptom free, partial improvement, and no improvement. results: Ninety‐seven patients (52 cetirizine, 45 fexofenadine) completed the study. The response to treatment in both the groups at the end of treatment period was as follows; symptom free {cetirizine 27(51.9%), fexofenadine 2(4.4%)}, partial improvement {cetirizine 19(36.5%), fexofenadine 19(42.2%)}, no improvement {cetirizine 6(11.5%), fexofenadine 24(53.3%)}. Side effects noted were mild with no significant difference between the two. conclusion: Cetirizine seems to have therapeutic advantage over fexofenadine in the treatment of CIU.

1 January 2011 in Indian Journal of Dermatology
Verified
Journal Article
Open access
PDF file
SHSanjeev Handa
Sanjeev Handa
DDDipankar De
Dipankar De
RMRahul Mahajan
Rahul Mahajan
The increasing recognition of occupational origin of airborne contact dermatitis has brought the focus on the variety of irritants, which can present with this typical morphological picture. At the same time, airborne allergic contact dermatitis secondary to plant antigens, especially to Compositae family, continues to be rampant in many parts of the world, especially in the Indian subcontinent. The recognition of the contactant may be difficult to ascertain and the treatment may be even more difficult. The present review focuses on the epidemiological, clinical and therapeutic issues in airborne contact dermatitis.

1 May 2024 in Vascular Health and Risk Management
Verified
Journal Article
Open access
PDF file
HMHitaishi Mehta
Hitaishi Mehta
TNTarun Narang
Tarun Narang
SDSunil Dogra
Sunil Dogra
SHSanjeev Handa
Sanjeev Handa
JHJuniali Hatwal
Juniali Hatwal
Akash BattaAkash Batta
Akash Batta
Psoriasis, a prevalent chronic inflammatory skin disorder affecting 2– 3% of the global population, has transcended its dermatological confines, revealing a profound association with cardiovascular diseases (CVD). This comprehensive review explores the intricate interplay between psoriasis and cardiovascular system, delving into genetic links, immune pathways, and adipose tissue dysfunction beyond conventional CVD risk factors. The pathophysiological connections unveil unique signatures, distinct from other inflammatory skin conditions, in particular psoriasis-specific genetic polymorphisms in IL-23 and TNF-α have consistently been linked to CVD. The review navigates the complex landscape of psoriasis treatments, addressing challenges and future directions in particular relevance to CVDs in psoriasis. Therapeutic interventions, including TNF inhibitors (TNFi), present promise in reducing cardiovascular risks, and methotrexate could constitute a favourable choice. Conversely, the relationship between IL-12/23 inhibitors and cardiovascular risk remains uncertain, while recent evidence indicates that Janus kinase inhibitors may not carry CVD risks. Emerging evidence supports the safety and efficacy of IL-17 and IL-23 inhibitors in patients with CVDs, hinting at evolving therapeutic paradigms. Lifestyle modifications, statins, and emerging therapies offer preventive strategies. Dedicated screening guidelines for CVD risk assessment in psoriasis are however lacking. Further, the impact of different disease phenotypes and treatment hierarchies in cardiovascular outcomes remains elusive, demanding ongoing research at the intersection of dermatology, rheumatology, and cardiology. In conclusion, unraveling the intricate connections between psoriasis and CVD provides a foundation for a holistic approach to patient care. Collaboration between specialties, advancements in screening methodologies, and a nuanced understanding of treatment impacts are essential for comprehensive cardiovascular risk management in individuals with psoriasis. Plain Language Summary: Psoriasis is a skin condition that not only affects the skin but is also linked to issues in the body’s fat tissue, which can lead to inflammation and heart problems. The fat tissue in people with psoriasis contains various immune cells, contributing to obesity and insulin resistance. Research has found a strong connection between inflammation in fat tissues and cardiovascular problems in people with psoriasis. Specific substances released by fat tissue, like leptin, resistin, and adiponectin, can impact inflammation and cardiovascular health. Psoriasis patients often show increased levels of these substances. Treatment for psoriasis may influence cardiovascular health. Some studies suggest that certain medications, like methotrexate or TNF inhibitors, may lower the risk of heart events. However, there are also concerns about potential adverse effects, and further research is needed to fully understand how psoriasis treatments affect cardiovascular outcomes. To manage the cardiovascular risks associated with psoriasis, regular screening for heart-related issues is recommended. Lifestyle changes, such as a healthy diet, stress management, and smoking cessation, are also essential. Additionally, specific medications, like statins and metformin, may be beneficial in controlling cardiovascular risk factors in people with psoriasis. Despite advancements in understanding the relationship between psoriasis and cardiovascular health, there are still challenges. Research is ongoing to develop better screening guidelines and treatment strategies. Collaboration between dermatologists, rheumatologists, and cardiologists is crucial to address the complex nature of this condition and its impact on the heart.